Full-Time

Associate Director

Global Patient Safety Operations

Posted on 11/27/2024

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$175k - $210kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Healthcare Administration & Support
Medical, Clinical & Veterinary
Required Skills
Data Analysis
Requirements
  • Bachelor’s degree in a healthcare field
  • Minimum of 7 years of relevant experience in pharmacovigilance operational activities
  • Hands-on experience working with CROs/vendors and management of external resources
  • Strong background in safety reporting regulatory compliance and global safety reporting/regulations in clinical trials
  • Able to problem solve, focus on details, multi-task, prioritize options, work independently, anticipate challenges and execute assigned deliverables
  • Ability to analyze situations and data that requires conceptual thinking and in-depth knowledge of organizational objectives
  • Ability to persuade others in sensitive/complex situations while maintaining relationships
  • An innovative team-player with capacity to be effective in a dynamic, continuously improving, and fast-paced company environment
  • Excellent interpersonal skills including ability to work in cross-functional team environments and with external vendors
  • Exercise discretion regarding highly confidential internal and external communications
Responsibilities
  • Develops and executes Global Patient Safety Operations operational objectives, policies, and procedures.
  • Participates in establishing strategic plans and objectives with senior management.
  • Collaborates with senior internal and external representatives to achieve objectives.
  • Represent Global Patient Safety in different cross functional team meetings.
  • Collaborate with other functional groups to achieve clinical program goals.
  • Oversee Pharmacovigilance Contract Research Organization (PV CRO) in the execution of safety reporting in clinical studies.
  • Manage PV CROs to ensure compliance with required timelines, that potential issues are being communicated, and resolution is achieved in a timely manner.
  • Oversee reporting of safety reports to global regulatory authorities, central IRB/ethics committees, investigators to ensure compliance with global regulatory requirements.
  • Ensure timely and accurate set up of global safety reporting and safety database in assigned clinical programs.
  • Support authoring and updates of clinical trial protocols, informed consent forms, Investigator Brochure (including the Reference Safety Information section), and aggregate reports.
  • Executes and maintains Safety Data Exchange Agreements/Pharmacovigilance Agreements with business partners.
  • Collaborate with other functional groups in SAE reconciliation and SAE query resolution activities.
  • Support Global Patient Safety team in other PV activities appropriate to experience and expertise.
  • Oversee or be responsible for one or more direct reports.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?